THE WOODLANDS, Texas,
June 5, 2017 /PRNewswire/
-- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced
today that new clinical data for sotagliflozin will be presented at
the upcoming 77th American Diabetes Association (ADA)
Scientific Sessions in San Diego,
CA, from June 9-13. The four
accepted abstracts, including two oral presentations, reflect
Lexicon's efforts to improve current approaches to the clinical
management of type 1 diabetes.
Lexicon will share new efficacy and safety data for its
investigational drug, sotagliflozin, including two late-breaking
abstracts from the inTandem2 and JDRF studies. In addition, there
will be two oral presentations on pivotal data from the inTandem1
study and additional data from the inTandem4 study.
- Saturday, June 10, 8:00am-10:00am, "GLP-1s and SGLT2s – To Do or
Not to Do in Type 1 Diabetes Mellitus"
-
- 8:00am: Twenty- Four Week
Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2
Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
(inTandem1) (#69-OR)
- 8:15am: A 12-Week Dose-Ranging
Study of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as
Adjunct Therapy to Insulin in Type 1 Diabetes (inTandem4)
(#70-OR)
- Sunday, June 11, 12:00pm-1:00pm, poster presentations
-
- Twenty- Four–Week Efficacy and Safety of Sotagliflozin, a Dual
SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1
Diabetes (inTandem2) (poster #146-LB)
- 12-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and
SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Young Adults with
Poorly Controlled Type 1 Diabetes (JDRF Study) (poster
#147-LB)
About Sotagliflozin
Discovered using Lexicon's unique approach to gene science,
sotagliflozin is a first-in-class, oral dual inhibitor of two
proteins responsible for glucose regulation known as sodium-glucose
co-transporter types 1 and 2 (SGLT1 and SGLT2). SGLT1 is
responsible for glucose absorption in the gastrointestinal tract,
and SGLT2 is responsible for glucose reabsorption by the
kidney.
Lexicon entered into a collaboration and license agreement with
Sanofi in November 2015 under which
Lexicon granted Sanofi an exclusive, worldwide (excluding
Japan), royalty-bearing right and
license to develop, manufacture and commercialize sotagliflozin.
Lexicon is responsible for all clinical development activities
relating to type 1 diabetes and retains an exclusive option to
co-promote and have a significant role, in collaboration with
Sanofi, in the commercialization of sotagliflozin for the treatment
of type 1 diabetes in the U.S. Sanofi is responsible for all
clinical development and commercialization of sotagliflozin for the
treatment of type 2 diabetes worldwide (excluding Japan) and is solely responsible for the
commercialization of sotagliflozin for the treatment of type 1
diabetes outside the U.S. (excluding Japan).
About Lexicon Pharmaceuticals
Lexicon is a fully integrated biopharmaceutical company that is
applying a unique approach to gene science based on Nobel
Prize-winning technology to discover and develop precise medicines
for patients with serious, chronic conditions. Through its
Genome5000™ program, Lexicon scientists have studied the role and
function of nearly 5,000 genes over the last 20 years and have
identified more than 100 protein targets with significant
therapeutic potential in a range of diseases. Through the precise
targeting of these proteins, Lexicon is pioneering the discovery
and development of innovative medicines to safely and effectively
treat disease. In addition to its recently-launched product for
carcinoid syndrome diarrhea, XERMELO™ (telotristat ethyl), Lexicon
has a pipeline of promising drug candidates in clinical and
pre-clinical development in diabetes and metabolism and neuropathic
pain. For additional information please visit
www.lexpharma.com.
Safe Harbor Statement
This press release contains "forward-looking statements,"
including statements relating to Lexicon's and its licensees'
clinical development of and regulatory filings for sotagliflozin
and the results and projected timing of clinical trials and the
potential therapeutic and commercial potential of sotagliflozin. In
addition, this press release also contains forward-looking
statements relating to Lexicon's growth and future operating
results, discovery and development of products, strategic alliances
and intellectual property, as well as other matters that are not
historical facts or information. All forward-looking statements are
based on management's current assumptions and expectations and
involve risks, uncertainties and other important factors,
specifically including the risk that clinical studies of
sotagliflozin may be halted, delayed or otherwise not demonstrate
safety or efficacy, the risk that the FDA and other regulatory
authorities may not grant regulatory approval of sotagliflozin in
accordance with Lexicon's currently anticipated timelines or at
all, and the risk that such regulatory approvals, if granted, may
have significant limitations on the approved use of sotagliflozin.
As a result, sotagliflozin may never be successfully
commercialized. Other risks include Lexicon's ability to meet its
capital requirements, successfully conduct preclinical and clinical
development and obtain necessary regulatory approvals of its other
potential drug candidates, achieve its operational objectives,
obtain patent protection for its discoveries and establish
strategic alliances, as well as additional factors relating to
manufacturing, intellectual property rights, and the therapeutic or
commercial value of its drug candidates. Any of these risks,
uncertainties and other factors may cause Lexicon's actual results
to be materially different from any future results expressed or
implied by such forward-looking statements. Information identifying
such important factors is contained under "Risk Factors" in
Lexicon's annual report on Form 10-K for the year ended
December 31, 2016, as filed with the
Securities and Exchange Commission. Lexicon undertakes no
obligation to update or revise any such forward-looking statements,
whether as a result of new information, future events or
otherwise.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/lexicon-pharmaceuticals-to-present-new-clinical-data-at-77th-american-diabetes-association-scientific-sessions-300468396.html
SOURCE Lexicon Pharmaceuticals, Inc.